Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer-Reference-Cited by-同舟云学术

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

Published:2016-06-10 Issue:1 Volume:158 Page:67-77
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Arun Banu K.,Gong Yun,Liu Diane,Litton Jennifer K.,Gutierrez-Barrera Angelica M.,Jack Lee J.,Vornik Lana,Ibrahim Nuhad K.,Cornelison Terri,Hortobagyi Gabriel N.,Heckman-Stoddard Brandy M.,Koenig Kimberly B.,Alvarez Ricardo R.,Murray James L.,Valero Vicente,Lippman Scott M.,Brown Powel,Sneige Nour

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3849-1.pdf

Reference34 articles.

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

2. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, Investigators NCMS (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391

3. Savage L (2007) Researchers wonder why high-risk women are not taking chemoprevention drugs. J Natl Cancer Inst 99:913–914